A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor activity and enhanced tumor-selectivity
用户0k7s_zqg7TRs
44分钟前
9
10
求助中
帖子自动结束时间: 2026-06-09 09:04:30
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
其他信息:
J Hou, T Gu, L Dong, J Tian, X Chen, D Liu…
Cancer …, 2026
aacrjournals.org
CEACAM5 and CDH17 are preferentially expressed in gastrointestinal tumors, including more than 95% of colorectal cancers, 80% of gastric and pancreatic cancers, and 70% of cholangiocarcinomas. Moreover, these two molecules are frequently co-expressed in gastrointestinal cancers. Recent advancements in CEACAM5 and CDH17 research have unveiled their potential as the promising targets for developing novel cancer therapeutics. Here we engineered a bispecific antibody (bsAb) capable of simultaneously binding to both …
